RARE · XBRL financial data

Ultragenyx Pharmaceutical financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RARE's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	271	351	363	434	560	673
Research and development	412	497	706	648	698	750
Selling, general and administrative	183	220	278	310	322	349
Total operating expenses	601	—	—	—	—	—
Operating income (loss)	(330)	(382)	(649)	(569)	(536)	(535)
Interest income	7	2	11	27	37	25
Other income (expense)	1	(2)	(2)	(0)	(4)	1
Income tax expense (benefit)	1	1	6	(2)	2	4
Net income (loss)	(187)	(454)	(707)	(607)	(569)	(575)
Earnings per share, basic USD per share	(3.07)	(6.70)	(10.12)	(8.25)	(6.29)	(5.83)
Earnings per share, diluted USD per share	(3.07)	(6.70)	(10.12)	(8.25)	(6.29)	(5.83)
Weighted average shares, basic millions of shares	61	68	70	74	91	99
Weighted average shares, diluted millions of shares	61	68	70	74	91	99

Fiscal years (RARE's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	714	308	133	214	174	421
Marketable securities	488	433	615	364	436	259
Marketable securities, non-current	11	259	149	200	135	57
Accounts receivable	23	28	40	73	122	158
Inventory	13	16	27	34	45	52
Prepaid and other current assets	58	72	69	48	40	61
Total current assets	1,295	857	884	732	817	951
Property and equipment, net	74	141	260	291	266	244
Right-of-use asset	41	35	26	24	26	23
Goodwill	44	44	44	44	44	44
Total assets	1,760	1,522	1,545	1,491	1,503	1,532
Accounts payable	13	17	43	42	39	31
Accrued liabilities	108	146	205	196	241	265
Total current liabilities	190	181	261	280	344	384
Lease liability, non-current	39	30	20	31	30	24
Total liabilities	605	600	1,193	1,216	1,241	1,605
Accumulated deficit	(1,620)	(2,074)	(2,781)	(3,388)	(3,957)	(4,532)
Total stockholders' equity	1,154	923	352	275	255	(80)
Total liabilities and equity	1,760	1,522	1,545	1,491	1,503	1,532
Common shares outstanding (cover page) millions of shares	67	69	70	82	93	97

Fiscal years (RARE's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(187)	(454)	(707)	(607)	(569)	(575)
Depreciation and amortization	12	13	18	26	36	35
Net cash from operating activities	(132)	(339)	(380)	(475)	(414)	(466)
Purchases of property and equipment	44	73	116	44	7	6
Net cash from investing activities	(179)	(195)	(292)	168	(18)	236
Proceeds from issuing common stock	436	0	0	—	—	—
Net cash from financing activities	600	119	501	388	399	478
Net change in cash	290	(417)	(172)	82	(35)	252

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Ultragenyx Pharmaceutical	125	214	(97)*	98.6M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Avidity Biosciences	383	0.9*	(170)*	155.1M	2.3 quarters	Q4 FY25 10-KDec 31, 2025
PERRIGO	400	1,023	83*	138.8M	—	Q2 FY26 10-QJun 27, 2026
Vaxcyte	183	not reported	(232)*	148.8M	6.4 quarters	Q2 FY26 10-QJun 30, 2026
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026
Viking Therapeutics	678	0	(138)*	127.5M	7.6 quarters	Q3 FY26 10-QSep 30, 2026
Prestige Consumer Healthcare	89	266	71	47.4M	—	Q1 FY27 10-QJun 30, 2026
Protagonist Therapeutics	420	213	219*	64.7M	—	Q2 FY26 10-QJun 30, 2026
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.